A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

Citation data:

Pediatric blood & cancer, ISSN: 1545-5017, Vol: 64, Issue: 11

Publication Year:
2017
Usage 17
Abstract Views 16
Link-outs 1
Captures 11
Exports-Saves 11
Social Media 3
Tweets 3
PMID:
28449393
DOI:
10.1002/pbc.26565
Author(s):
Geller, James I, Perentesis, John P, Liu, Xiaowei, Minard, Charles G, Kudgus, Rachel A, Reid, Joel M, Fox, Elizabeth, Blaney, Susan M, Weigel, Brenda J
Publisher(s):
Wiley-Blackwell
Tags:
Medicine
Most Recent Tweet View All Tweets
article description
The c-Met receptor tyrosine kinase is dysregulated in many pediatric cancers. Tivantinib is an oral small molecule that inhibits the c-Met receptor tyrosine kinase. A phase 1 and pharmacokinetic (PK) trial evaluating tivantinib was conducted in children with relapsed/refractory solid tumors.

This article has 0 Wikipedia mention.